Multiple Sclerosis Detected by Analysis of Exhaled Breath
|
By LabMedica International staff writers Posted on 23 Aug 2012 |
A sensor array has been developed that can diagnose multiple sclerosis (MS) from exhaled breath.
Scientists identified volatile organic compounds from exhaled breath that can be associated with MS. Based on these findings they developed a sensor array that can diagnose MS by analyzing the compounds that appear in the breath of MS patients. The cross-reactive array of polycyclic aromatic hydrocarbons and single wall carbon-nanotube bilayers were designed for the detection of volatile organic compounds (hexanal and 5-methyl-undecane) that identify the presence of disease in the exhaled breath of patients with MS.
Using the sensors, the scientists carried out a proof-of-concept clinical study on 34 MS patients and 17 healthy volunteers and found that the developed sensors are just as accurate as a lumbar puncture but without the pain or the risk of side effects. Results obtained from the study showed that the sensors could discriminate between MS and healthy states from exhaled breath samples with 85.3% sensitivity, 70.6% specificity, and 80.4% accuracy.
Initiator and coordinator of the study, Prof. Hossam Haick at the department of chemical engineering and Russell Berrie Nanotechnology Institute, Technion–Israel Institute of Technology (Haifa, Israel) and colleagues report that doctors currently diagnose MS according to clinical symptoms, which include muscle spasms, numbness, coordination problems, and slurred speech. Confirmation of the diagnosis is made by either magnetic resonance imaging (MRI), which is costly, or lumbar puncture, which is invasive and can be painful with unpleasant side effects.
The study was published in the journal ACS Chemical Neuroscience in 2012.
Related Links:
Technion–Israel Institute of Technology
Scientists identified volatile organic compounds from exhaled breath that can be associated with MS. Based on these findings they developed a sensor array that can diagnose MS by analyzing the compounds that appear in the breath of MS patients. The cross-reactive array of polycyclic aromatic hydrocarbons and single wall carbon-nanotube bilayers were designed for the detection of volatile organic compounds (hexanal and 5-methyl-undecane) that identify the presence of disease in the exhaled breath of patients with MS.
Using the sensors, the scientists carried out a proof-of-concept clinical study on 34 MS patients and 17 healthy volunteers and found that the developed sensors are just as accurate as a lumbar puncture but without the pain or the risk of side effects. Results obtained from the study showed that the sensors could discriminate between MS and healthy states from exhaled breath samples with 85.3% sensitivity, 70.6% specificity, and 80.4% accuracy.
Initiator and coordinator of the study, Prof. Hossam Haick at the department of chemical engineering and Russell Berrie Nanotechnology Institute, Technion–Israel Institute of Technology (Haifa, Israel) and colleagues report that doctors currently diagnose MS according to clinical symptoms, which include muscle spasms, numbness, coordination problems, and slurred speech. Confirmation of the diagnosis is made by either magnetic resonance imaging (MRI), which is costly, or lumbar puncture, which is invasive and can be painful with unpleasant side effects.
The study was published in the journal ACS Chemical Neuroscience in 2012.
Related Links:
Technion–Israel Institute of Technology
Latest Clinical Chem. News
- Saliva-Based Test Detects Biochemical Signs of Sleep Loss
- Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
- Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
- Urine-Based Test Shows Promise for Autism Screening in Children
- Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s
- Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
- Urine-Based Alzheimer’s Test Receives FDA Breakthrough Device Designation
- Fluid Biomarker Improves Diagnosis and Monitoring of Primary CNS Lymphoma
- New CA19-9 Cutoff Value Helps Identify High-Risk Pancreatic Cancer Patients
- Blood-Based Biomarkers Show Promise for Psychosis Risk Prediction
- International Experts Recommend Ending Routine 'Corrected' Calcium Reporting
- Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths
- Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
- FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
- CE-Marked Blood Biomarker Test Advances Automated Alzheimer’s Diagnostics
- Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
Channels
Molecular Diagnostics
view channel
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read more
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more








